Expression of serum CTRP3 in patients with progressive cerebral infarction and its correlation with inflammatory factors

doi:10.3877/cma.j.issn.2095-123X.2019.02.006

Abstract

Abstract:

Objective

To observe the changes of serum C1q/TNF-related protein 3 (CTRP3) in patients with progressive cerebral infarction (PCI) and to explore its clinical value.

Methods

Fifty-five patients with PCI were selected as the research group, fifty-five healthy subjects were selected as the control group. The levels of tumor necrosis factor alpha (TNF-α), interleukin-6 (IL-6) and CTRP3 were compared between the two groups before and after treatment by enzyme-linked immunosorbent assay (ELISA).

Results

The levels of TNF-α and IL-6 in research group were higher than those in control group (P<0.05). The level of CTRP3 in the research group was lower than that in control group (P<0.05). CTRP3 has a negative correlation between TNF-α and IL-6 levels (r=-0.351, P=0.009; r=-0.465, P=0.003), respectively. After treatment, the levels of TNF-α and IL-6 in PCI group were decreased, and the level of CTRP3 was increased (P<0.05), CTRP3 has a negative correlation between TNF-α and IL-6 levels (r=-0.326, P=0.015; r=-0.569, P=0.001), respectively.

Conclusion

The level of serum CTRP3 in patients with PCI was decreased, and CTRP3 levels was increased after treatment, and it is negatively correlated with the levels of TNF-α and IL-6. It is suggested that CTRP3 may be involved in the pathophysiological process of brain injury after PCI. The detection of serum CTRP3 may have important clinical significance in assisting to judge the prognosis of PCI.

Key words: C1q/TNF-related protein 3, Progressive cerebral infarction, Tumor necrosis factor α, Interleukin-6

Bolin Li, Chunna Liang, Wenjing Tan, Yanpeng Ruan, Mingjun Liang, Fuhua Xie. Expression of serum CTRP3 in patients with progressive cerebral infarction and its correlation with inflammatory factors[J]. Chinese Journal of Brain Diseases and Rehabilitation(Electronic Edition), 2019, 09(02): 87-90.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhnkjbykfzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-123X.2019.02.006

https://zhnkjbykfzz.cma-cmc.com.cn/EN/Y2019/V09/I02/87

Figures/Tables 3

References 16

[1]	Schiefecker AJ, Rass V, Gaasch M, et al. Brain extracellular interleukin-6 levels decrease following antipyretic therapy with diclofenac in patients with spontaneous subarachnoid hemorrhage[J]. Ther Hypothermia Temp Manag, 2018, 9(1): 48-55.
[2]	马大威.凝血指标、炎症因子和CRP检测对进展性脑梗死患者的临床意义[J].国际检验医学杂志, 2014, 35(8): 1059-1060.
[3]	Li Y, Wright GL, Peterson JM. C1q/TNF-related protein 3 (CTRP3) function and regulation[J]. Compr Physiol, 2017, 7(3): 863-878.
[4]	梁伟，赵雅洁，田书雅,等.补体C1q/肿瘤坏死因子相关蛋白3对糖代谢异常患者冠状动脉病变程度的影响[J].上海医学, 2017, 40(4): 234-237.
[5]	Wei WY, Ma ZG, Zhang N, et al. Overexpression of CTRP3 protects against sepsis-induced myocardial dysfunction in mice[J]. Mol Cell Endocrinol, 2018, 476: 27-36.
[6]	薛丹. CTRP3在糖脂代谢及心血管保护作用中的研究进展[J].心血管病学进展, 2018, 39(3): 435-437.
[7]	Wang R, Wei Y, Teng J. Levels of plasma N-terminal pro-brain natriuretic peptide and D-dimer on the prognosis of patients with acute cerebral infarction[J]. Pak J Med Sci, 2018, 34(4): 855-858.
[8]	雷虹，张洁，王瑾瑜,等.补体C1q/肿瘤坏死因子相关蛋白家族研究进展[J].生理科学进展, 2015, 46(1): 43-48.
[9]	Nishimoto H, Yamamoto A, Furukawa S, et al. C1q/TNF-related protein 3 expression and effects on adipocyte differentiation of 3T3-L1 cells[J]. Cell Biol Int, 2016, 41(2): 197-203.
[10]	冯寒，张城林，吴丹,等. CTRP3通过抑制Smad3通路和肌成纤维细胞转化减轻心肌梗死后心肌纤维化[J].中国病理生理杂志,2015, 15(10): 1793.
[11]	Yuan YP, Ma ZG, Zhang X, et al. CTRP3 protected against doxorubicin-induced cardiac dysfunction, inflammation and cell death via activation of Sirt1[J]. J Mol Cell Cardiol, 2018, 114: 38-47.
[12]	王婉秋，孙侃，靳瑾,等. 2型糖尿病性动脉粥样硬化大鼠血浆VEGF、TGF-β1、CTRP3的表达及辛伐他汀的干预作用[J].天津医药, 2015, 43(4): 370-374.
[13]	Lin J, Liu Q, Zhang H, et al. C1q/Tumor necrosis factor-related protein-3 protects macrophages against LPS-induced lipid accumulation, inflammation and phenotype transition via PPARγ and TLR4-mediated pathways[J]. Oncotarget, 2017, 8(47): 82541-82557.
[14]	Trogen G, Bacon J, Li Y, et al. Transgenic overexpression of CTRP3 prevents alcohol-induced hepatic triglyceride accumulation[J]. Am J Physiol Endocrinol Metab, 2018, 315(5): E949-E960.
[15]	王丽萍，宋斌，戴燕,等. C1q/TNF相关蛋白3、脂联素与2型糖尿病胰岛素抵抗的相关性[J].中国老年学杂志, 2018, 38(11): 2597-2599.
[16]	Petersen PS, Wolf RM, Lei X, et al. Immunomodulatory roles of CTRP3 in endotoxemia and metabolic stress[J]. Physiol Rep, 2016, 4(5): e12735.

组别	例数	TNF-α（pg/mL）	IL-6（pg/mL）	CTRP3（ng/mL）
研究组	55	102.60±19.85	114.7±26.22	129.65±53.21
对照组	55	9.70±2.34	21.44±4.99	326.50±61.06
t值	?	34.470	25.877	18.032
P值	?	0.001	0.001	0.001

组别	例数	TNF-α（pg/mL）	IL-6（pg/mL）	CTRP3（ng/mL）
研究组	55	102.60±19.85	114.7±26.22	129.65±53.21
对照组	55	9.70±2.34	21.44±4.99	326.50±61.06
t值	?	34.470	25.877	18.032
P值	?	0.001	0.001	0.001

组别	例数	TNF-α（pg/mL）	IL-6（pg/mL）	CTRP3（ng/mL）
治疗前	55	102.60±19.85	114.57±26.22	129.65±53.21
治疗后	55	20.95±6.00	39.74±9.30	258.40±66.17
t值	?	29.206	19.946	11.244
P值	?	0.001	0.001	0.001

组别	例数	TNF-α（pg/mL）	IL-6（pg/mL）	CTRP3（ng/mL）
治疗前	55	102.60±19.85	114.57±26.22	129.65±53.21
治疗后	55	20.95±6.00	39.74±9.30	258.40±66.17
t值	?	29.206	19.946	11.244
P值	?	0.001	0.001	0.001

Please choose a citation manager

Content to export